Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

1.

Combination therapy for the treatment of Crohn's disease.

Mosli MH, Feagan BG.

Expert Opin Biol Ther. 2015 Jul 27:1-14. [Epub ahead of print]

PMID:
26211474
2.

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.

Gottlieb K, Travis S, Feagan B, Hussain F, Sandborn WJ, Rutgeerts P.

Inflamm Bowel Dis. 2015 Jun 18. [Epub ahead of print]

PMID:
26086596
3.

Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions.

Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B.

Clin Gastroenterol Hepatol. 2015 Jun 11. pii: S1542-3565(15)00787-9. doi: 10.1016/j.cgh.2015.06.001. [Epub ahead of print]

4.

Assessment of mucosal healing in inflammatory bowel disease: review.

Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ.

Gastrointest Endosc. 2015 Aug;82(2):246-55. doi: 10.1016/j.gie.2015.03.1974. Epub 2015 May 21. Review.

PMID:
26005012
5.

Briakinumab for treatment of Crohn's disease: results of a randomized trial.

Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R.

Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. doi: 10.1097/MIB.0000000000000366.

6.

C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG.

Am J Gastroenterol. 2015 Jun;110(6):802-819. doi: 10.1038/ajg.2015.120. Epub 2015 May 12. Review.

PMID:
25964225
7.

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].

Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ.

J Crohns Colitis. 2015 Aug;9(8):607-16. doi: 10.1093/ecco-jcc/jjv077. Epub 2015 May 8.

PMID:
25956538
8.

Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.

Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG.

Gut. 2015 May 2. pii: gutjnl-2014-308973. doi: 10.1136/gutjnl-2014-308973. [Epub ahead of print]

PMID:
25935574
9.

Vedolizumab for the treatment of moderately to severely active ulcerative colitis.

Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG.

Pharmacotherapy. 2015 Apr;35(4):412-23. doi: 10.1002/phar.1561.

PMID:
25884529
10.

Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.

Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, Khanna R, Feagan BG.

Inflamm Bowel Dis. 2015 May;21(5):1151-9. doi: 10.1097/MIB.0000000000000396.

PMID:
25844963
11.

Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.

Khanna R, Feagan BG.

Expert Opin Drug Saf. 2015 Jun;14(6):987-97. doi: 10.1517/14740338.2015.1029915. Epub 2015 Mar 29.

PMID:
25819509
12.

Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.

Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group.

Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4. Review.

PMID:
25747596
13.

Clinical remission as defined by the Mayo Score: do we deceive ourselves?

Samaan MA, Feagan BG, Sandborn WJ, Levesque BG.

Inflamm Bowel Dis. 2015 Jan;21(1):E3-4. doi: 10.1097/MIB.0000000000000294. No abstract available.

PMID:
25479461
14.

The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.

Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R, Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K.

Clin Gastroenterol Hepatol. 2015 May;13(5):928-35.e2. doi: 10.1016/j.cgh.2014.10.031. Epub 2014 Nov 6.

PMID:
25460016
15.

Reproducibility of histological assessments of disease activity in UC.

Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG.

Gut. 2014 Oct 30. pii: gutjnl-2014-307536. doi: 10.1136/gutjnl-2014-307536. [Epub ahead of print]

PMID:
25360036
16.

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.

Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG.

Gut. 2014 Oct 21. pii: gutjnl-2014-307883. doi: 10.1136/gutjnl-2014-307883. [Epub ahead of print]

17.

Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?

Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG.

Inflamm Bowel Dis. 2014 Nov;20(11):2132-41. doi: 10.1097/MIB.0000000000000218. Review.

PMID:
25299543
18.

A phase II study of laquinimod in Crohn's disease.

D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators.

Gut. 2015 Aug;64(8):1227-35. doi: 10.1136/gutjnl-2014-307118. Epub 2014 Oct 3.

19.

Current issues in the design of clinical trials in IBD.

Feagan BG.

Nestle Nutr Inst Workshop Ser. 2014;79:19-28. doi: 10.1159/000360670. Epub 2014 Sep 5.

PMID:
25227292
20.

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W.

Gastroenterology. 2014 Dec;147(6):1296-1307.e5. doi: 10.1053/j.gastro.2014.08.035. Epub 2014 Aug 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk